0
Товары в корзине
Итого:
Information block example
Consultation
Request a call
Working hours:
Mon-Fri 9: 00-23: 00;
Sat-Sun 10: 00-20: 00

Qurled and Qurdac

Qurled and Qurdac
Brand:
Strides

Brand name: Qurled Qurdac 

Active components: Qurled-Sofosbuvir, Qurdac-Daclatasvir

Strength of the components: 400mg & 60mg respectively

Mfg: Strides

Package: 28 tablets in a container

Category: Anti-hepaciviral drug

Specifications
Manufacture:
Strides
Active substance:
Sofosbuvir and Daclatasvir
In stock
Sku: ---
0 $
Available options:
Amount:
Add to Wishlist
Add to Compare
Consultation:+91 (994) 0472902
Description

Drug profile

Qurled Qurdac tablets are anti-viral medication, containing two most predominant ingredients such as Sofosbuvir and Daclatasvir

Qurled Qurdac  tablets are single dose therapy, it is a prescription medicine used by the patients only under the knowledge of medical practitioner who are well practiced

Qurdac  tablet is not used alone, for better action it should be combined with Qurled tablet.

In some condition Qurled Qurdac  is combined with ribavirin, an anti-viral medicine used in decompensated (Child Pugh B or C) cirrhosis

 

Brand name: Qurled Qurdac 

Active components: Qurled-Sofosbuvir, Qurdac-Daclatasvir

Strength of the components: 400mg & 60mg respectively

Mfg: Strides

Package: 28 tablets in a container

Category: Anti-hepaciviral drug

 

Prescribing information for Qurled Qurdac

The main indication of Qurled Qurdac  is;

This combination tablets are used to treat the chronic hepatitis C viral infection caused by genotype I or III

The major limitation occurred while using Qurled Qurdac  tablets are reduction of constant virological response rate in hepatitis C genotype I or III infected patients.

 

Mechanism of Qurled Qurdac

The activity of Qurled Qurdac  tablets are occurred by involving in some mechanism;

Qurled:

Qurled containing sofosbuvir has anti-hepaciviral activity, which is directly acting drug exhibits its action by prohibiting NS5B RNA reliant RNA polymerase enzyme; essential for hepatitis viral multiplication.

Sofosbuvir is metabolized to form uridine triphosphate, an essential active metabolite which exposes an anti-viral activity.

The infusion of this active metabolite into hepatitis viral RNA with the help of NS5B polymerase and causes viral chain discontinuation

Qurdac:

Qurdac containing Daclatasvir expels anti-viral activity by prohibiting NS5A protein which is needful in viral production and virion accumulation

 

Absorption

The peak plasma concentration of Qurdac tablets occurs within the range of 2 hours

The absolute bioavailability of Qurdac is 67%

The peak plasma concentration of Qurled tablets occurs within the range of 0.5 to 2 hours approximately.

The food will not creates any variation in absorption of Qurled Qurdac  tablets, may be taken with or without food

 

Distribution

The volume of distribution in Qurdac tablet is 47L

The human plasma protein bound with Qurdac tablet is nearly 99%

The blood to plasma ratio of Qurled is relatively 0.7

The human plasma protein bound with Qurled occurs nearly 61 to 65%

 

Metabolism

Qurled is metabolized hepatically and formed as pharmacologically active metabolite uridine triphosphate, metabolism undergone with the help of cathepsin A or carboxylesterase 1

Qurdac metabolism occurred with the help of CYP3A4

 

Elimination

88% of Daclatasvir is excreted through feces 53% as an unchanged form, 6.6% excreted through urine.

The terminal half life period of Daclatasvir is occurred at 12 to 15 hours

Sofosbuvir metabolites are excreted through 80% in urine, 14% in feces & 2.5% in exhaled air

The terminal half life period of sofosbuvir is nearly 0.51 hours

 

How to take the Tablet Qurled Qurdac

Qurled Qurdac  tablets are administered with or without food, in the condition of hepatitis C viral infection originated by genotype I or III

Qurled Qurdac  is single dose regimen

 

Dosage regimens

Generally Daclatasvir is not used alone, it is combined with sofosbuvir

The recommended dosage of Qurled Qurdac  is one tablet should be taken as a single dose

If sofosbuvir is discontinued, Daclatasvir also get stopped

Genotype III:

Patient suffered without cirrhosis or with compensated cirrhosis:

The recommended dosage of Qurled Qurdac  is one tablet should be taken as a single dose with or without food (400mg/60mg)

In decompensated cirrhosis patients:

Qurled Qurdac  should be combined with ribavirin as a single dose (400mg/60mg)

Genotype I:

Patient suffered without cirrhosis or with compensated cirrhosis:

The recommended dosage of Qurled Qurdac  is one tablet should be taken as a single dose with or without food

In decompensated cirrhosis patients:

Qurled Qurdac  should be combined with ribavirin as a single dose

The dosage of ribavirin;

On basis of body weight & hemoglobin level of patients, dose can be calculated.

Less than 75kg: 1000mg of ribavirin; in genotype I or III 600mg of ribavirin as an initial dose and followed as 1000mg/per

At least 75 kg: in decompensated cirrhosis 1200mg of ribavirin given as twice daily

The safety and efficacy of Qurdac has not been established <18 years

Virso used in ≥12 years or weight of ≥35kg

 

Dosage adjustment due to drug interaction;

If concurrent use with strong CYP3A inhibitors, the dosage of Qurdac is reduced to 30mg while co administration

Concurrent use with moderate CYP3A inducers, the dosage of Qurdac increased to 90mg

Concomitant use of Qurdac with CYP3A strong inducers should be avoided, it is contraindicated

 

Qurled Qurdac caused side effects

The most common side effects occurred during the therapy;

Cardiac problems like symptomatic bradycardia

Insomnia

Pruritus

Myalgia

Elevation of lipase

Loss of appetite

Irritability

Neutropenia

Anemia

Chills

Influenza like symptoms

Pyrexia

Pancytopenia

Asthenia

Rashes

Headache

Fatigue

Nausea

Diarrhea

 

Drug interaction

Qurled Qurdac  tablets concomitant with amiodarone causes serious symptomatic bradycardia

Qurled Qurdac  tablets concomitant with anti-convulsants, anti-mycobacterials or herbal products like st Johns wort causes decrease in effect of concentration of Qurled Qurdac 

While combining Qurled Qurdac  with strong CYP3A inducers causes loss of virological reaction rate of both products

If Qurled combines with P-gp or BCRP inhibitors leads to cause elevation of sofosbuvir plasma concentration

Qurled Qurdac  with HMG CoA reductase inhibitors, this combination leads to cause increasing the exposure of these drugs (statins)

CYP3A strong inducers like st Johns wort, rifampin, phenytoin or carbamazepine

 

Food drug interaction

Qurled Qurdac  with herbal product like st. Johns wort causes decreasing the therapeutic effect of Qurled Qurdac 

Diet should be discussed with consultant while undergoing therapy

No food drug interaction occurs

While using Qurled Qurdac  tablets, caution should be taken

 

Possible contraindications

Some contraindications occurs while using Qurled Qurdac  tablets

In decompensated cirrhosis, combines with ribavirin contraindicated in pregnancy condition

Some anaphylactic reaction occurs if patients are contraindicated to the components present in Qurled Qurdac 

 

Safety measures

Using Qurled Qurdac  with ribavirin, should not be recommended in pregnancy condition because of producing fetal damage due to ribavirin

Qurled Qurdac  causes serious bradycardia while concurrent use with amiodarone, to prevent this condition some alternative medicine is given or discontinue the amiodarone if possible. Counsel the patients about the exposure of bradycardia during the treatment

While taking Qurled Qurdac  tablets, with CYP3A strong inducers causes loss of therapeutic response of Qurled Qurdac  tablets. Avoid this concomitant to reduce the adverse effects

 

Pregnancy and lactation

Qurled Qurdac  use in pregnancy, safe to use. The pregnancy category is B1

While combining with ribavirin, not recommended for pregnancy

Pregnancy category: X, causes fetal death

 Breast feeding should not be recommended

 

Storage and handling

The storage condition of Qurled Qurdac  should be stored at room temperature below 30oC (86oF) & 20oC and 25oC (68oF and 77oF) respectively

Container should be keep away from heat, light and moisture

 

Missed dose

Both Qurled Qurdac  tablets are single dose therapy, if patient fails to take the dose of these tablets, must consult the physician and take the dose within the time as per the instruction given by medical practitioner

Otherwise the missed dose should be skipped and follow the regular dosing schedule

 

Over dosage

The over dosage of Qurled Qurdac  tablets are occurred due to missed dose , if once over dosage occurs the patients must be monitored frequently for endorsement of toxicity and provide safety measures

Hemodialysis is a procedure used to eliminate the component from body, sofosbuvir removes with separation coefficient of 54% whereas Daclatasvir is problematic because nearly 99% of drug bounded to human plasma protein

 

Specifications
Manufacture
Strides
Active substance
Sofosbuvir and Daclatasvir
Qurled and Qurdac reviews
Write a review
0 comments

There are no comments yet

We use cookies to make the site better for you